Epidemiological and clinical aspects of patients with <i>Neoscytalidium</i> spp. dermatomycoses in Switzerland

Leuthard, Deborah S.; Walther, Matthias; Galliker, Nadja; Bosshard, Philipp P.

doi:10.1111/jdv.15836

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dermatomycosis caused by Neoscytalidium dimidiatum (originally Hendersonula toruloidea and renamed Scytalidium dimidiatum) is prevalent in tropical regions, including Central Africa, Southeast Asia, and South America 1,2) , and found in countries with a history of immigrants from, or domestic travelers to, these regions 3,4) . Although there has been no report of disease by this pathogen in Japan, N. dimidiatum is not a rare causative fungi, being described as a major pathogen of foot dermatomycosis in Tobago and Thailand 5,6) , and of non-dermatophyte mold onychomycosis in Colombia and Malaysia 7,8) .…”

Section: Introductionmentioning

confidence: 99%

First Isolation of Neoscytalidium dimidiatum from Human Dermatomycosis in Japan

Futatsuya

Ogawa²,

Anzawa

et al. 2022

Medical Mycology Journal

View full text Add to dashboard Cite

Neoscytalidium dimidiatum is a common fungus that causes non-dermatophyte dermatomycosis in tropical regions, but there have been no reports of infection with N. dimidiatum in Japan. Here, we report the first isolation of N. dimidiatum from human dermatomycosis in Japan. A 62-year-old healthy Japanese male had been treated with oral terbinafine for tinea pedis diagnosed from a microscopic examination in 2003 with a lesion that was intractable. In 2020, re-identification by sequencing the internal transcribed spacer regions and the D1/D2 domain of the large-subunit (LSU) ribosomal RNA gene revealed that the pathogen was N. dimidiatum. Antifungal susceptibility tests showed that the minimum inhibitory concentration of the drug luliconazole (LLCZ) against the pathogen was 0.00049 µg/mL. The patient's lesions were cured by topical LLCZ. The clinical course and drug susceptibility suggest that LLCZ is a suitable first-line drug for treatment.

show abstract